Vismodegib Identified as a Novel COX-2 Inhibitor via Deep-Learning-Based Drug Repositioning and Molecular Docking Analysis

Abstract

Artificial intelligence algorithms have been increasingly applied in drug development due to their efficiency and effectiveness. Deep-learning-based drug repurposing can contribute to the identification of novel therapeutic applications for drugs with other indications. The current study used a trained deep-learning model to screen an FDA-approved drug library for novel COX-2 inhibitors. Reference COX-2 data sets, composed of active and decoy compounds, were obtained from the DUD-E database. To extract molecular features, compounds were subjected to RDKit, a cheminformatic toolkit. GraphConvMol, a graph convolutional network model from DeepChem, was applied to obtain a predictive model from the DUD-E data sets. Then, the COX-2 inhibitory potential of the FDA-approved drugs was predicted using the trained deep-learning model. Vismodegib, an anticancer agent that inhibits the hedgehog signaling pathway by binding to smoothened, was predicted to inhibit COX-2. Noticeably, some compounds that exhibit high potential from the prediction were known to be COX-2 inhibitors, indicating the prediction model’s liability. To confirm the COX-2 inhibition activity of vismodegib, molecular docking was carried out with the reference compounds of the COX-2 inhibitor, celecoxib, and ibuprofen. Furthermore, the experimental examination of COX-2 inhibition was also carried out using a cell culture study. Results showed that vismodegib exhibited a highly comparable COX-2 inhibitory activity compared to celecoxib and ibuprofen. In conclusion, the deep-learning model can efficiently improve the virtual screening of drugs, and vismodegib can be used as a novel COX-2 inhibitor.

Discovery of Novel Aldose Reductase Inhibitors via the Integration of Ligand-Based and Structure-Based Virtual Screening with Experimental Validation

“…The positioning of a ligand within a protein’s holo structure is a key determinant of the protein’s binding pocket . The aldose reductase and inhibitor (fidarestat) complex already available on PDB (PDB ID: 1PWM) was further utilized for binding pocket analysis.…”

“…The positioning of a ligand within a protein’s holo structure is a key determinant of the protein’s binding pocket. 43 The aldose reductase and inhibitor (fidarestat) complex already available on PDB (PDB ID: 1PWM ) was further utilized for binding pocket analysis. The identification of interacting amino acids was accomplished through Discovery Studio’s ligand interaction approach, ensuring precision in the generation of the binding site.…”

The Millennia-Long Development of Drugs Associated with the 80-Year-Old Artificial Intelligence Story: The Therapeutic Big Bang?

“…It is also popular to use trained models to screen the FDA-approved drugs’ library. A good example of it is the use of graph convolutional networks to find potential inhibitors of a target among all FDA-approved drugs [ 182 ].…”

Discovery of GABA Aminotransferase Inhibitors via Molecular Docking, Molecular Dynamic Simulation, and Biological Evaluation

“…Molecular docking is a widely employed method for assessing the interactions and conformations of ligands when binding to target proteins [35]. Molecular docking predicts the strength of association or binding compatibility between a ligand and protein by considering their preferred orientation and employing scoring algorithms [28].…”